Connect with us

otc

Aurora Cannabis Inc. (ACBFF: OTCQX International) | Aurora Announces 2017 AGM Voting Results

Published

on

All Items of Business Approved
Aurora Welcomes Diane Jang to Board

TSX: ACB

VANCOUVER, Nov. 14, 2017 /CNW/ – Aurora Cannabis Inc. (the “Company” or “Aurora” or the “Issuer”) (TSX: ACB) (OTCQX: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) today announced the voting results from its Annual General and Special Meeting of Tradebuddy.onlineholders (the “Meeting”), held in Edmonton, Alberta, on November 13, 2017. The total number of shares represented by shareholders present in person and by proxy at the meeting was 88,726,591 million representing 23.86 per cent of Aurora’s issued and outstanding Common Tradebuddy.onlines.

All of the matters put forward before shareholders for consideration and approval as set out in the Company’s Management Information Circular dated October 6, 2017, were approved by the requisite majority of votes cast at the Meeting. The details of the voting results for the election of directors are set out below:

Nominee

# Votes for

% Votes for

# Votes withheld

% Votes withheld

Michael Singer

44,975,439

92.61%

3,591,454

7.39%

Terry Booth

45,135,102

92.93%

3,431,791

7.07%

Steve Dobler

44,397,421

91.41%

4,169,472

8.59%

Dr. Jason Dyck

45,145,502

92.96%

3,421,391

7.04%

Adam Szweras

48,177,434

99.20%

389,459

0.80%

Joseph del Moral

45,070,158

92.80%

3,496,735

7.20%

Diane Jang

48,189,124

99.22%

377,769

0.78%

 

The shareholders also approved the: (i) re-appointment of MNP LLP as auditors of the Company for the ensuing year; (ii) non-binding advisory vote on the Company’s approach to executive compensation; (iii) Company’s Fixed Restricted Tradebuddy.online Unit Plan (“RSU”) and RSU awards; and (iv) new form 10% “Rolling” Tradebuddy.online Option Plan and the grant of all currently available and unallocated option entitlements.

The Company has filed a report of voting results on all resolutions voted on at the Meeting on www.sedar.com.

Diane Jang

Aurora is pleased to welcome Diane Jang to its Board of Directors. Ms. Jang is the newly appointed CEO of Hempco Food and Fiber, commencing in her new role in December 2017. She is an experienced business executive, specializing in strategic planning for sustainable success, growth and profitability for companies. With over 27 years of business experience in the Consumer Packaged Goods industry in premium foods and plant-based protein, she has a proven track record in strategic planning, increasing profitability and leading companies to become market leaders in their industries. Previously, Ms. Jang led successful companies as President at Sunrise Soya Foods and General Manager at Earth’s Own Food Co Inc., and also serves as a Director of Big Sisters of BC Lower Mainland. Ms. Jang holds a Bachelor of Business Administration from Simon Fraser University.

“We are very pleased with the election of Diane to our Board,” said Terry Booth, CEO. “She brings a wealth of leadership experience in Consumer Packaged Goods, having successfully led companies to become leaders in their respective industry sectors.  This is a strength that we will leverage in executing our strategy in regard the commencement of sales of cannabis for adult recreational use. We look forward to working closely with Diane.”

Ms. Jang added, “Serving on the Board of Aurora, a globally dominant cannabis company, in such an exciting sector with such great potential, is a fantastic opportunity, and I look forward to contributing towards the further growth of the Company.”

Options grant

The Company granted stock options to certain directors and officers to purchase 640,000 common shares under the Company’s Tradebuddy.online Option Plan. The options are exercisable at a price of $4.64 per share, vest evenly every quarter over three years commencing November 13, 2017 and expire five years from the date of grant.

About Aurora

Aurora’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta, known as “Aurora Mountain”, a second 40,000 square foot high-technology production facility known as “Aurora Vie” in Pointe-Claire, Quebec on Montreal’s West Island, and is currently constructing an 800,000 square foot production facility, known as “Aurora Sky”, at the Edmonton International Airport.
In addition, the Company holds approximately 9.6% of the issued shares (12.9% on a fully-diluted basis) in leading extraction technology company Radient Technologies Inc., based in Edmonton, and is in the process of completing an investment in Edmonton-based Hempco Food and Fiber for an ownership stake of up to 50.1%. Furthermore, Aurora is the cornerstone investor with a 19.9% stake in Cann Group Limited, the first Australian company licensed to conduct research on and cultivate medical cannabis. Aurora also owns Pedanios, a leading wholesale importer, exporter, and distributor of medical cannabis in the European Union, based in Germany. The Company offers further differentiation through its acquisition of BC Northern Lights Ltd. and Urban Cultivator Inc., industry leaders, respectively, in the production and sale of proprietary systems for the safe, efficient and high-yield indoor cultivation of cannabis, and in state-of-the-art indoor gardening appliances for the cultivation of organic microgreens, vegetables and herbs in home and professional kitchens. Aurora’s common shares trade on the TSX under the symbol “ACB”.

On behalf of the Board of Directors,
AURORA CANNABIS INC.

Terry Booth
CEO

This news release contains certain “forward-looking statements” within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements include, but are not limited to, the successful completion of the Offering and the use of proceeds of the Offering and the Company’s intention to continue international and domestic expansion. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law. A more complete discussion of the risks and uncertainties facing the Company appears in the Company’s Annual Information Form and continuous disclosure filings, which are available at www.sedar.com.

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Aurora Cannabis Inc.

Copyright © 2017 PR Newswire. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

otc

Orexo AB (ORXOY: OTCQX International) | Orexo completes early redemption of existing bond loan

Published

on

 

 

Orexo completes early redemption of existing bond loan

Nov 22, 2017

OTC Disclosure & News Service

Stockholm, Uppsala, Sweden

This release includes additional documents. Select the link(s) below to view.

Press release Orexo completes early redemption of existing bond loan publ. 22.11.2017.pdf

Copyright © 2017 OTC Markets. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Continue Reading

otc

Orexo AB (ORXOY: OTCQX International) | Orexo Completes Early Redemption of Existing Bond Loan

Published

on

UPPSALA, Sweden, Nov. 22, 2017 /PRNewswire/ — Orexo AB (publ.) (the “Company”) today announces that the Company, in accordance with Orexo’s press release on 31 October 2017, has completed the early total redemption of the existing bond loan (ISIN SE0005932159).

The redemption was made at an amount corresponding to 101 percent of the nominal amount (i.e. SEK 1,010,000 per bond, the nominal amount being SEK 1,000,000) together with accrued but unpaid interest from the preceding interest payment date on November 9 2017 up to, and including, the redemption date on November 22 2017. In conjunction herewith, the bonds are delisted from the corporate bond list of Nasdaq Stockholm.

For further information, please contact:

Orexo AB   (publ.)

Nikolaj Sørensen, President and CEO                         
Tel: +46 (0)18-780-88-00                                              
E-mail: ir@orexo.com                                                   

Henrik Juuel, EVP and CFO
Tel: + 46 (0)18-780-88-00
E-mail: ir@orexo.com

About Orexo

Orexo develops improved pharmaceuticals based on innovative drug delivery technologies. The focus is primarily on opioid dependence and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The main market today is the US market for the treatment of opioid dependence where the product Zubsolv® is commercialized by Orexo. Other products are commercialized by license partners, including Zubsolv in markets outside of the US. Total net sales for 2016 amounted to SEK 705.9 million and the number of employees was 102. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) index and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where also research and development is performed, is located in Uppsala, Sweden.

For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube. For more information about Zubsolv in the US, see the product and market websites www.zubsolv.com  and www.rise-us.com

The information was submitted for publication at 8:30 am CET, November 22, 2017

This information was brought to you by Cision http://news.cision.com
http://news.cision.com/orexo/r/orexo-completes-early-redemption-of-existing-bond-loan,c2396751

The following files are available for download:

 

View original content:http://www.prnewswire.com/news-releases/orexo-completes-early-redemption-of-existing-bond-loan-300560846.html

SOURCE Orexo

Copyright © 2017 PR Newswire. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Continue Reading

Recent Posts

Trending